Skip to main content
Gene Therapy Net RSS feed Follow Gene Therapy Net on Twitter LinkedIn - Gene Therapy Net discussion group Facebook - Gene Therapy Net
 

European Commission Approves Novartis’ Kymriah CAR-T Cell Therapy

Posted on: 29 August 2018, source: Novartis
Novartis announced that the European Commission (EC) approved its chimeric antigen receptor T cell (CAR-T) cell therapy Kymriah (tisagenlecleucel) for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.